Zimmer Biomet Announces First Quarter 2026 Financial Results
Zimmer Biomet reported Q1 net sales of $2.09 billion, up 9.3% reported and 2.9% organic constant currency, driven by healthy end markets and new product momentum. Adjusted diluted EPS increased 15.5% to $2.09, leading the company to raise its full-year adjusted EPS guidance to $8.40-$8.55.
Key figures
- Eps
- 1.22
- Revenue
- $2.087 billion
- Guidance
- FY26 Adjusted Diluted EPS raised to $8.40 - $8.55 from $8.30 - $8.45
- Revenue Yoy
- 9.3%
- Adjusted eps
- 2.09
- Free cash flow
- $245.9 million
- Shares repurchased
- $250 million
- Operating cash flow
- $359.4 million
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.